- Home
- CASI
as 12-26-2024 4:00pm EST
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
| Founded: | 1991 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 58.8M | IPO Year: | 1996 |
| Target Price: | $6.00 | AVG Volume (30 days): | 56.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.05 - $8.19 | Next Earning Date: | 11-15-2024 |
| Revenue: | $22,055,000 | Revenue Growth: | -47.82% |
| Revenue Growth (this year): | -40.4% | Revenue Growth (next year): | 134.79% |
Latest CASI Pharmaceuticals Inc. News
CASI Breaking Stock News: Dive into CASI Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
ACCESSWIRE
a month ago
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
GuruFocus.com
a month ago
CASI Pharmaceuticals Inc (CASI) Q3 2024 Earnings Report Preview: What To Expect
MT Newswires
2 months ago
Casi Pharmaceuticals Says China Cleared Phase 1/2 Trial in Immune Thrombocytopenia
ACCESSWIRE
2 months ago
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia
Simply Wall St.
3 months ago
CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week
PR Newswire
4 months ago
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
PR Newswire
4 months ago
CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS
Compare CASI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CASI CASI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.